The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Relapse after HSCT 2021 | Patient selection for CAR-T therapy
Sergio Giralt, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses patient selection for chimeric antigen receptor T-cell (CAR-T) therapy, highlighting key challenges. This interview took place at the 2021 Relapse After HSCT² Workshop in New York, NY.
Disclosures
Sergio Giralt, MD, PhD, discloses links to Amgen, Janssen, Celgene, Quintiles, Pfizer, CSL Behring, Sanof, Adienne, Kite, JAZZ and Actinuum.
